Brief: Nordic Nanovector To Discontinue Paradigme, Its Phase 2B Trial With Betalutin In 3L R And R Follicular Lymphoma

Thor Medical ASA

05/07/2022 20:30

July 5 (Reuters) - Nordic Nanovector ASA  NANOVN.OL :
    * NORDIC NANOVECTOR TO DISCONTINUE PARADIGME, ITS PHASE 2B
TRIAL
WITH BETALUTIN ®  IN 3L R AND R FOLLICULAR LYMPHOMA
    * NO FURTHER PATIENTS WILL BE ENROLLED INTO PARADIGME
    * SAYS COMPANY WILL NOW ENSURE A WIND-DOWN OF PARADIGME IN A
STRUCTURED MANNER
    * BOARD HAS ALSO DECIDED TO IMPLEMENT A RESTRUCTURING OF
COMPANY
WITH IMMEDIATE EFFECT
    * NORDIC NANOVECTOR - WILL EXPLORE POTENTIAL PARTNERSHIPS,
SEEK
ADVICE FROM US FDA TO DISCUSS IF THERE COULD BE A POSSIBLE WAY
FORWARD FOR BETALUTIN
    * WILL NOW FOCUS ITS EFFORTS AND RESOURCES ON DEVELOPING ITS
PIPELINE OF PROPRIETARY CD37-TARGETING PRODUCTS

Source text for Eikon:  ID:nWkrvw5hQ 
Further company coverage:  NANOVN.OL 

 ((Reuters.Briefs@thomsonreuters.com;))